Die Kosten der präoperativen Anämie bei Hüftgelenkrevisionsoperationen

Translated title of the contribution: The Costs of Preoperative Anemia in Hip Joint Revision Surgery

Gerald Vorderwülbecke, Claudia Spies, Christian von Heymann*, Jochen Kruppa, Daniel Fürstenau, Lutz Kaufner, Sven Werner, Moritz Höft, Felix Balzer*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

9 Downloads (Pure)


Anemia is highly prevalent in patients before hip joint revision surgery (HJRS) and is associated with an increased complication rate. This paper is the first to investigate costs, real diagnosis-related group (DRG) revenues and case coverage of preoperative anemia in elective HJRS.

Medical data, transfusions, costs, and revenues of all patients undergoing HJRS at two campuses of the Charité –Universitätsmedizin Berlin between 2010 and 2017 were used for subgroup analyses and linear regressions.

Of 1187 patients included 354 (29.8%) showed preoperative anemia. A total of 565 (47.6%) patients were transfused with a clear predominance of anemic patients (72.6% vs. 37.0%, p 
Preoperative anemia and perioperative transfusions in HJRS are associated with increased treatment costs and a financial undercoverage for healthcare providers and health insurance companies. Concepts for the treatment of preoperative anemia (e.g. patient blood management) could reduce treatment costs in the medium term.
Translated title of the contributionThe Costs of Preoperative Anemia in Hip Joint Revision Surgery
Original languageGerman
Issue number1
Pages (from-to)13–20
Number of pages8
Publication statusPublished - Jan 2023

Bibliographical note

Published online:15 November 2022.


  • Patient blood managment
  • Red blood cells
  • Transfusion
  • Revenue
  • DRG system

Cite this